Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND -0.50%11 Gross Margin % is 53.13% as of Mar. 2026, which is 22% below its 10-year median of 68.24. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Vyome Holdings ranks worse than 57.65% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vyome Holdings had a gross margin of 53.13% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vyome Holdings Gross Margin % Related Terms
Vyome Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HIND vs CTXR, MBRX, AKTX: Gross Margin % Comparison
For the Biotechnology subindustry, Vyome Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vyome Holdings (HIND) has a Gross Margin % of 53.13% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vyome Holdings and its competitors. This is 22% below median its historical median of 68.24. Over the past decade, Vyome Holdings' Gross Margin % has ranged from 38.12 to 75.88. According to the industry distribution chart, Vyome Holdings ranks #422 out of 732 companies in the Biotechnology industry, placing it in the top 57.7%.
Is Vyome Holdings' Gross Margin % too high?
Vyome Holdings' current Gross Margin % of 53.13% is 22% below median its 10-year median of 68.24. Over the past 10 years, this metric has ranged from a low of 38.12 to a high of 75.88. The Biotechnology industry median Gross Margin % is 60.92. Vyome Holdings' value of 53.13% is 12.8% below this industry median. Based on the distribution chart, Vyome Holdings ranks #422 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Gross Margin % compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #422 out of 732 companies for Gross Margin %. This places Vyome Holdings in the lower half of its industry. The industry median Gross Margin % is 60.92. Vyome Holdings' value of 53.13% is 12.8% below this benchmark. Historically, Vyome Holdings' own Gross Margin % has ranged from 38.12 to 75.88 over the past decade. While the company's 10-year median is 68.24 vs. the industry median of 60.92, Vyome Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vyome Holdings's current Gross Margin % of 53.13% is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vyome Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vyome Holdings's current Gross Margin % is 53.13%, which is 22% below median its own 10-year median of 68.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Gross Margin % of 53.13%. The current Gross Margin % is 53.13%, which is 22% below median its 10-year median of 68.24 and 12.8% below the Biotechnology industry median of 60.92. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Gross Margin % is 53.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
